Universal Beteiligungs und Servicegesellschaft mbH Grows Position in Regeneron Pharmaceuticals, Inc. $REGN

Universal Beteiligungs und Servicegesellschaft mbH grew its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 108,871 shares of the biopharmaceutical company’s stock after buying an additional 827 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH owned 0.10% of Regeneron Pharmaceuticals worth $84,179,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Meyer Handelman Co. raised its stake in Regeneron Pharmaceuticals by 0.6% in the 4th quarter. Meyer Handelman Co. now owns 2,878 shares of the biopharmaceutical company’s stock worth $2,221,000 after acquiring an additional 18 shares during the last quarter. CoreCap Advisors LLC grew its stake in Regeneron Pharmaceuticals by 9.2% during the 3rd quarter. CoreCap Advisors LLC now owns 238 shares of the biopharmaceutical company’s stock valued at $134,000 after purchasing an additional 20 shares during the last quarter. Whittier Trust Co. increased its holdings in shares of Regeneron Pharmaceuticals by 5.9% in the fourth quarter. Whittier Trust Co. now owns 357 shares of the biopharmaceutical company’s stock valued at $277,000 after purchasing an additional 20 shares during the period. Strait & Sound Wealth Management LLC increased its holdings in shares of Regeneron Pharmaceuticals by 3.5% in the third quarter. Strait & Sound Wealth Management LLC now owns 628 shares of the biopharmaceutical company’s stock valued at $353,000 after purchasing an additional 21 shares during the period. Finally, Parkside Financial Bank & Trust raised its stake in shares of Regeneron Pharmaceuticals by 14.8% in the third quarter. Parkside Financial Bank & Trust now owns 163 shares of the biopharmaceutical company’s stock worth $92,000 after purchasing an additional 21 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages recently commented on REGN. Wall Street Zen lowered Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, April 11th. Morgan Stanley lifted their price objective on shares of Regeneron Pharmaceuticals from $769.00 to $796.00 and gave the company an “equal weight” rating in a research note on Friday, April 10th. Evercore upped their price objective on shares of Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the company an “outperform” rating in a report on Thursday, January 22nd. Wells Fargo & Company increased their price objective on shares of Regeneron Pharmaceuticals from $745.00 to $800.00 and gave the stock an “equal weight” rating in a research note on Monday, February 2nd. Finally, Truist Financial reduced their target price on shares of Regeneron Pharmaceuticals from $818.00 to $801.00 and set a “buy” rating for the company in a report on Tuesday, March 31st. Two analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $811.96.

Key Stories Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Major label expansions for Dupixent — U.S. approval as the first biologic for children 2–11 with uncontrolled chronic spontaneous urticaria (CSU) and a recent European Commission approval broaden pediatric indications, supporting additional addressable market and revenue tailwinds. Dupixent US Approval Dupixent EU Approval
• Positive Sentiment: Cemdisiran phase‑3 success in generalized myasthenia gravis (gMG) — strong NIMBLE trial results (published in The Lancet) and a submitted U.S. regulatory application point to a high‑value pipeline asset and potential first‑in-class siRNA approval. Cemdisiran Phase 3
• Positive Sentiment: Analyst commentary expects EPS growth and a likely earnings beat, which could provide upside if results and guidance exceed consensus. Earnings Preview
• Neutral Sentiment: Regeneron is hosting investor events and presenting at major conferences (BofA, Goldman Sachs) in May–June — useful for management commentary but may only cause short‑term moves. Investor Presentations
• Neutral Sentiment: Company discussion/transcript on the C5 complement program (cemdisiran + pozelimab) provides technical and clinical detail for investors assessing pipeline optionality. C5 Program Transcript
• Negative Sentiment: Valuation and momentum concerns — analysis notes that recent approvals and collaborations (including a Telix radiopharmaceutical tie‑up) are in place but shares have underperformed year‑to‑date, suggesting some investors view these wins as already priced in or insufficient to change longer‑term growth trajectory. That skepticism is likely weighing on the stock. Valuation Analysis

Regeneron Pharmaceuticals Stock Down 0.1%

REGN stock opened at $746.58 on Thursday. The firm’s fifty day moving average is $764.22 and its 200 day moving average is $729.68. The firm has a market cap of $78.93 billion, a PE ratio of 17.96, a P/E/G ratio of 1.66 and a beta of 0.40. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $821.11. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.39 and a current ratio of 4.13.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $10.74 by $0.70. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The business had revenue of $3.88 billion for the quarter, compared to analyst estimates of $3.76 billion. During the same period in the prior year, the company posted $12.07 EPS. The company’s revenue for the quarter was up 2.5% on a year-over-year basis. On average, research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.2 EPS for the current year.

Regeneron Pharmaceuticals Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 5th. Shareholders of record on Friday, February 20th were issued a $0.94 dividend. The ex-dividend date of this dividend was Friday, February 20th. This is an increase from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. This represents a $3.76 annualized dividend and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio is 9.05%.

Insider Activity

In other news, Director Huda Y. Zoghbi sold 1,638 shares of the company’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $781.33, for a total transaction of $1,279,818.54. Following the completion of the transaction, the director directly owned 1,703 shares of the company’s stock, valued at $1,330,604.99. This represents a 49.03% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, SVP Jason Pitofsky sold 2,036 shares of the stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $778.52, for a total value of $1,585,066.72. Following the transaction, the senior vice president owned 4,272 shares in the company, valued at $3,325,837.44. This trade represents a 32.28% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 3,774 shares of company stock worth $2,942,738 over the last three months. 7.02% of the stock is currently owned by corporate insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.